# Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)

> **NCT06333210** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Biocad** · enrollment: 421 (estimated)

## Conditions studied

- Axial Spondyloarthritis

## Interventions

- **BIOLOGICAL:** anti-TRBV9 monoclonal antibody infusions
- **OTHER:** Placebo infusions
- **DRUG:** Adalimumab subcutaneous injection
- **OTHER:** Placebo subcutaneous injection

## Key facts

- **NCT ID:** NCT06333210
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-25
- **Primary completion:** 2024-12
- **Final completion:** 2028-02
- **Target enrollment:** 421 (ESTIMATED)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06333210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06333210, "Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06333210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*